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Addition of rice bran arabinoxylan to curcumin therapy may be of benefit
to patients with early-stage B-cell lymphoid malignancies (monoclonal
gammopathy of undetermined significance, smoldering multiple
myeloma, or stage 0/1 chronic lymphocytic leukemia): a preliminary
clinical study
Abstract
Hypothesis. Prior studies on patients with early B-cell lymphoid malignancies suggest that early intervention
with curcumin may lead to delay in progressive disease and prolonged survival. These patients are
characterized by increased susceptibility to infections. Rice bran arabinoxylan (Ribraxx) has been shown to
have immunostimulatory, anti-inflammatory, and proapoptotic effects. We postulated that addition of Ribraxx
to curcumin therapy may be of benefit.
Study design. Monoclonal gammopathy of undetermined significance (MGUS)/smoldering multiple
myeloma (SMM) or stage 0/1 chronic lymphocytic leukemia (CLL) patients who had been on oral curcumin
therapy for a period of 6 months or more were administered both curcumin (as Curcuforte) and Ribraxx.
Methods. Ten MGUS/SMM patients and 10 patients with stage 0/1 CLL were administered 6 g of curcumin
and 2 g Ribraxx daily. Blood samples were collected at baseline and at 2-month intervals for a period of 6
months, and various markers were monitored. MGUS/SMM patients included full blood count (FBC);
paraprotein; free light chains/ratio; C-reactive protein (CRP)and erythrocyte sedimentation rate (ESR); B2
microglobulin and immunological markers. Markers monitored for stage 0/1 CLL were FBC, CRP and ESR,
and immunological markers.
Results. Of 10 MGUS/SMM patients,5 (50%) were neutropenic at baseline, and the Curcuforte/Ribraxx
combination therapy showed an increased neutrophil count, varying between 10% and 90% among 8 of the
10 (80%) MGUS/SMM patients. An additional benefit of the combination therapy was the potent effect in
reducing the raised ESR in 4 (44%) of the MGUS/SMM patients.
Conclusion. Addition of Ribraxx to curcumin therapy may be of benefit to patients with early-stage B-cell
lymphoid malignancies.
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Introduction
Studies with patients with early B-cell lymphoid malignan-
cies—that is, monoclonal gammopathy of undetermined sig-
nificance (MGUS), smoldering multiple myeloma (SMM), or 
stage 0/1 chronic lymphocytic leukemia (CLL)—have been 
carried out in our clinics from 2010 to 2015. Our results 
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Abstract
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infections. Rice bran arabinoxylan (Ribraxx) has been shown to have immunostimulatory, anti-inflammatory, and proapoptotic 
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patients who had been on oral curcumin therapy for a period of 6 months or more were administered both curcumin 
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markers. Markers monitored for stage 0/1 CLL were FBC, CRP and ESR, and immunological markers. Results. Of 10 MGUS/
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neutrophil count, varying between 10% and 90% among 8 of the 10 (80%) MGUS/SMM patients. An additional benefit of the 
combination therapy was the potent effect in reducing the raised ESR in 4 (44%) of the MGUS/SMM patients. Conclusion. 
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suggest that early intervention with curcumin may lead to 
delay in progressive disease and prolonged survival in some of 
these patients.1-6 Multiple myeloma and its precursor dis-
eases—that is, MGUS/SMM—account for approximately 1% 
of neoplastic diseases and 13% of hematological cancers in 
Western countries.7 CLL is the most common type of leukemia 
in the Western world.8 Patients with early phases of these 
B-cell disorders are routinely monitored in a “watch and wait” 
modality. For these patients, a low risk of disease progression, 
the potential for drug-related toxicity, and the failure to achieve 
a complete remission does not justify conventional chemother-
apy as a therapeutic option. They represent an excellent group 
to determine whether early intervention with nontoxic nutra-
ceutical agents with known chemopreventive, anti-inflamma-
tory, and/or immunostimulatory effects may be of benefit.
Patients with these early B-cell lymphoid malignancies are 
characterized by increased susceptibility to infections; in part, 
this results from a disruption in the normal processes for syn-
thesis of immunoglobulins.9 Typically, CLL patients exhibit 
impaired antibody production, often resulting in pan- or par-
tial hypogammaglobulinemia. In multiple myeloma, the 
malignant plasma cells elaborate a single species of immuno-
globulin and/or a monoclonal light chain. In contrast, the 
polyclonal antibody synthesis required for protection against 
bacterial infection is often impaired. Thus, these patients can 
be considered “functionally” hypogammaglobulinemic.9
A number of nutraceutical agents have been shown to 
have an immunostimulatory, anti-inflammatory, and/or pro-
apoptotic effect, and combining their action with curcumin 
may be synergistic. Rice bran arabinoxylan (Ribraxx)—a 
proprietary formulation of rice bran and shitake mushroom 
extract—has been extensively studied and found to have 
immune stimulating, anti-inflammatory, and proapoptotic 
effects.10-19A clinical study by Cholujova et al20 on 48 
myeloma patients showed that Ribraxx, at a dose of 2 g/d, 
increased NK cell activity, increased the level of mDCs in the 
peripheral blood, and augmented levels of Th-1–related cyto-
kines in the plasma of these patients compared with a placebo 
group. An invitro study by Ghoneum and Gollapudi21 showed 
that Ribraxx and curcumin synergized in the induction of 
apoptosis of the U266 human multiple myeloma cell line. 
Based on the above findings, we proposed to recruit 10 
patients with MGUS/SMM and 10 patients with stage 0/1 
CLL who had been taking curcumin for a period of 6 months 
or more prior to the study and who had reached a stable 
response status as determined by markers of disease progres-
sion and administer both curcumin (as Curcuforte C3 com-
plex) and Ribraxx in order to determine whether Ribraxx 
either induces or improves the clinical response.
Methods
A total of 10 MGUS/SMM patients (as defined by the 
International Myeloma Working Group) and 10 patients 
with stage 0/1 CLL with significant lymphocytosis 
(>15×109lymphocytes/L) and Rai stage 0 (early CLL and 
lymphocytosis) or stage 1 (CLL and lymphadenopathy) 
were recruited. All the patients in the study had been on oral 
curcumin therapy (600mg to 6g daily) for a period of 6 
months or more and had reached a stable disease response 
as determined by markers of disease progression. For the 
MGUS/SMM patients, this included paraprotein, total pro-
tein, free light chains, and percentage plasma cells; for the 
stage 0/1 CLLpatients, this included absolute lymphocyte 
count (ALC). All the patients in the study had provided 
written informed consent before study enrolment in accor-
dance with the Declaration of Helsinki. The protocols for 
the curcumin studies with MGUS/SMM patients 
(ACTRN12610000962033) and the stage 0/1 CLL patients 
(ACTRN12615000487516) were reviewed and approved 
by the South Eastern Sydney and Illawarra ethics 
committee.
They were administered 6 g of curcumin (as Curcuforte, 
in a divided dose) and 2 g Ribraxx (in a divided dose) daily. 
Blood samples were collected at baseline and at 2-month 
intervals for a period of 6 months. Markers monitored for 
the MGUS/SMM patients included FBC, paraprotein, free 
light chains/ratio, C-reactive protein (CRP)and erythrocyte 
sedimentation rate (ESR), B2 microglobulin, and immuno-
logical markers, including serum immunoglobulins (sIgGs) 
and surface leukocyte markers. Markers monitored for 
stage 0/1 CLL were FBC, CRP and ESR, and immunologi-
cal markers, including sIgGs and surface leukocyte 
markers.
Serum paraprotein and immunoglobulin-electrophoresis 
was determined by agarose gel (Sebia, Cedex, France); 
serum B2 microglobulin was measured using Beckman 
instruments (Beckman Instruments, Fullerton, CA); FLC 
analysis was performed by immunonephelometry using 
specific antibodies (the binding site) on a BNII nephelom-
eter (Dade Behring, Deerfield, Illinois); CD4, CD8, and NK 
cell counts were determined by flow cytometry using 
Beckman instruments.
Curcumin (as Curcuforte) and Ribraxx were supplied by 
BioMedica Nutraceuticals.
Results
Monoclonal Gammopathy of Undetermined 
Significance/Smoldering Multiple Myeloma
A total of 10 patients were recruited—6 men and 4 women, 
with a mean age 68.5 years. Four patients diagnosed with 
IgA MGUS/SMM, 4 with IgG MGUS/SMM, and 2 with 
light chain disease (Table 1). All 10 patients completed the 
study. Two patients developed diarrhea on the combination 
therapy and stopped taking curcumin but continued with 
Ribraxx only (patients 3 and 9). One patient developed 
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abnormal liver function markers, stopped the curcumin 
therapy, and continued with Ribraxx only (patient 6).
During the 6-month study period, markers such as para-
protein, total protein, free light chains, B2 microglobulin, 
and CRP showed nonsignificant fluctuating levels (Table 2). 
A number of immunological markers were monitored over 
the 6-month study period (Table 3). The serum IgG, IgM, 
and IgA showed no significant changes, but the neutrophil 
count increased in 8/10 (80%) patients (P< .05, Table 4). 
Five of these patients (50%; patients 1,3,5,6,9) were neutro-
penic at baseline, and all demonstrated an increase in neu-
trophil count varying between 10% and 90% over the 6 
months (Table 4). Patient 3, 6, and 9 were on Ribraxx only. 
Some of the patients with a normal baseline neutrophil 
count also showed an increase on the Curcuforte/Ribraxx 
combination therapy.
Of 9 MGUS/SMM patients,6 (67%) had an elevated 
ESR at baseline (Table 5; data not available for patient 6). 
Two patients (1 and 4) showed >80% reduction in their ESR 
levels at month 2 with combination therapy (Table 5); one 
of these (number 4) showed a subsequent increase in ESR, 
whereas patient 1 maintained a >80% decrease at 6 months. 
Two patients (9 and 10) showed a >20% reduction in ESR 
from baseline at 6 months (Table 5).
CD4 and CD8 T-cell counts were available for 9/10 
MGUS/SMM patients during the course of the study (data 
not available for patient 6; Tables 6 and 7). Seven of these 
(77%) had normal baseline CD4 and CD8 counts (CD4 = 
0.4×109/L to 1.4×109/L; CD8 = 0.2×109/L to 0.9×109/L). 
Whereas most patients showed fluctuating counts during 
the course of the study, patients 1,7, and 10 showed a >40% 
increase in CD4 and CD8 T-cell numbers at the end of the 
Table 1. Patient Demographics.
Patient 
No. Age Sex Paraprotein Type
MGUS/SMM
 1 55 M IgAk
 2 74 F IgGk
 3 62 M IgGL
 4 65 F IgAk
 5 70 M Light chain disease
 6 65 F IgGk
 7 65 M IgAL
 8 70 M IgGL
 9 73 M Light chain disease
10 86 F IgAk
Patient 
No. Age Sex
Absolute Lymphocyte Count at 
Baseline (1×109/L to 4×109/L)
Stage 0/1 CLL
 1 55 M 63.6
 2 37 M 36.5
 3 72 M 15.4
 4 70 M 16.8
 5 68 M 54.7
 6 83 M 17.6
 7 66 M 29.3
 8 80 M 44.3
 9 72 F 31
10 80 F 51.8
Abbreviations: MGUS, monoclonal gammopathy of undetermined 
significance; SMM, smoldering multiple myeloma; CLL, chronic 
lymphocytic leukemia.
Table 2. Mean (±SD) Values of Paraprotein, Total Protein, 
ESR, and CRP in MGUS/SMM Patients Over the 6-Month Study 
Period.
Baseline Month 2 Month 4 Month 6
Paraproteina 23.6 ± 12.8 26.9 ± 19.3 24.4 ± 17.1 27.6 ± 20.7
Total proteinb 80.2 ± 15.9 81.2 ± 20.4 78.4 ± 17.2 82.2 ± 21.8
(64-83 g/L)
ESRb 50.3 ± 44.5 27.9 ± 17.5 42.3 ± 35.9 45.6 ± 41.7
(1-20 mm/h)
CRPb 4.6 ± 6.1 4.0 ± 4.7 4.6 ± 6.1 5 ± 5
(0-5 mg/L)
Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; 
MGUS, monoclonal gammopathy of undetermined significance; SMM, smoldering 
multiple myeloma.
an=8.
bn=10.
Table 3. Mean (±SD) Values of Immunological Markers in the 
10 MGUS/SMM Patients Over the 6-Month Study Period.
Baseline Month 2 Month 4 Month 6
Neutrophil 2.8 ± 2 3.3 ± 1.9 3.5 ± 2.4 3.3 ± 1.8
(2 × 109/L to 7 
× 109/L)
IgG 14.6 ± 13.2 14.5 ± 13.9 14.1 ± 13.1 14.9 ± 14.1
(6.2-14.4g/L)
IgA 10.1 ± 16.1 11 ± 17.9 10.7 ± 19.0 12.6 ± 21.9
(0.6-3.96 g/L)
IgM 0.29 ± 0.18 0.27 ± 0.18 0.27 ± 0.16 0.27 ± 0.19
0.48-3.04 g/L
CD4a 0.79 ± 0.49 0.93 ± 0.58 0.71 ± 0.3 0.79 ± 0.39
(0.4 × 109/L to 
1.4 × 109/L)
CD8a 0.27 ± 0.13 0.31 ± 0.13 0.28 ± 0.17 0.33 ± 0.19
(0.2 × 109/L to 
0.9 × 109/L)
NKa 0.31 ± 0.16 0.32 ± 0.14 0.25 ± 0.12 0.29 ± 0.18
(0.05 × 109/L 
to 0.6 × 
109/L)
Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; 
SMM, smoldering multiple myeloma; IgG, immunoglobulin G; IgA, immunoglobulin 
A; IgM, immunoglobulin M; NK, natural killer cells.
an=9.
 at Prince of Wales Hospital on May 8, 2016ict.sagepub.comDownloaded from 
4 Integrative Cancer Therapies 
6-month study period (Tables 6 and 7). NK cell counts fluc-
tuated over the course of the study but showed no signifi-
cant changes (Tables 3 and 8).
Stage 0/1 CLL
A total of 10 stage 0/1 CLL patients with an ALC>15 ×109/L 
(normal = 1×109/L to 4×109/L) were recruited into the 
study. There were 8 men and 2 women, with a mean age of 
68 years (Table 1). One patient withdrew because of diffi-
culties with administering the large number of tablets, and 1 
patient developed severe diarrhea and was administered 
Ribraxx only (patient 7).Mean values of the various hema-
tological markers (FBC, CRP and ESR, sIgGs, and surface 
leukocyte markers) over the course of the study are shown 
in Table 9.
Whereas most patients showed fluctuating ALCs 
(Table 10), patient number 6 showed a 42% decrease in 
ALC over the 6 months while on the Curcuforte/Ribraxx 
therapy, and patient number 9 showed a 29% decrease in 
ALC but withdrew because of shingles, which developed at 
4 months after the combination therapy.
Neutrophil counts of all 9 patients with stage 0/1 CLL 
were normal at baseline (Table 4). One patient (number 8) 
showed an increase in neutrophil count over the 6 months, 
whereas the remaining 8 patients showed stable or fluctuat-
ing neutrophil counts, with no significant change. There 
was no significant change in the sIgGs—that is, IgG, IgM, 
and IgA—over the study period (Table 9).
Table 4. Individual Neutrophil Countsa Over the 6-Month 
Study Period.
Patient 
Number Baseline
Month  
2
Month 
4
Month 
6
Percentage
Change From 
Baseline
MGUS/SMM
 1 0.89 0.62 1.04 1.44 62
 2 6.41 6.67 7.1 4.77 −25
 3b 1.91 2.84 2.83 2.47 29
 4 2.26 2.88 8.07 3.08 36
 5 0.94 2.52 1.17 1.72 83
 6b 1.7 1.6 1.9 1.9 12
 7 3.4 3.7 3.4 6.4 88
 8 4.74 5.17 4.05 5.45 15
 9b 0.83 1.68 1.3 1.52 83
10 4.99 4.84 3.85 4.48 −10
Stage 0/1 CLL
 1 5.16 8.21 4.91 6.08 18
 2 9.1 5.87 4.59 5.32 −42
 3 4.6 4.13 5.55 3.75 −19
 4 3.05 2.89 2.55 3.52 15
 5 3.8 3.9 3.4 2.9 −24
 6 4.5 4.9 4.1 4.42 −2
 7b 4.52 5.69 4.31 5.13 13
 8 2.2 6.3 5.04 7.56 244
 9 2.94 2.26 2.33 −21
Abbreviations: MGUS, monoclonal gammopathy of undetermined 
significance; SMM, smoldering multiple myeloma; CLL, chronic 
lymphocytic leukemia.
aNormal =2×109/Lto 7×109/L
bRibraxx only.
Table 5. Individual ESR Valuesa in MGUS/SMM Patients Over 
the 6-Month Study Period.
Patient 
Number Baseline
Month 
2
Month 
4
Month 
6
Percentage 
Change From 
Baseline
 1 130 24 7 11 –92
 2 43 34 36 84 95
 3b 10 25 16 12 20
 4 106 2 105 117 10
 5 5 7 7 7 40
 7 4 30 26 18 350
 8 59 62 64 91 54
 9b 63 39 90 50 −21
10 33 28 30 20 –39
Abbreviations: ESR, erythrocyte sedimentation rate; MGUS, monoclonal 
gammopathy of undetermined significance; SMM, smoldering multiple 
myeloma.
aNormal = 1-30mm/h.
b Ribraxx only.
Table 6. Individual CD4 T-cell Countsa Over the 6-Month 
Study Period.
Patient 
Number Baseline
Month 
2
Month 
4
Month 
6
Percentage 
Change From 
Baseline
MGUS/SMM
 1 0.42 0.36 0.52 0.63 50
 2 1.64 2.2 1.2 1.45 –12
 3b 0.64 0.76 0.76 0.7 9
 4 1.46 1.27 0.75 1.18 –19
 5 1 1.02 0.66 0.83 –17
 7 0.47 1.06 0.98 0.85 81
 8 0.82 0.95 0.9 10
 9b 0.38 0.38 0.18 0.18 –53
10 0.3 0.41 0.47 0.51 70
Stage 0/1 CLL
 1 5.09 3.01 1.7 4.84 –5
 2 1.46 3.54 1.55 1.55 6
 3 0.92 1.18 1.21 32
 4 1.34 0.86 1.28 1.06 –21
 5 1.64 1.83 1.49 1.71 4
 6 3.22 3.04 1.95 2.38 –26
 7b 2.22 3.32 2.48 2.06 –7
 8 2.93 2.93 3.61 4.04 38
 9 5.18 3.82 2.96 –43
Abbreviations: MGUS, monoclonal gammopathy of undetermined 
significance; SMM, smoldering multiple myeloma; CLL, chronic 
lymphocytic leukemia.
aNormal = 0.4×109/Lto 1.4×109/L.
bRibraxx only.
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Baseline CD4, CD8 T-cell, and NK cell counts were 
elevated in 7/9 (78%) of stage 0/1 CLL patients, in accor-
dance with previous findings (Tables 6-8). Most showed 
fluctuating counts during the study, with patient numbers 3 
and 8 demonstrating an increase in CD4, CD8, and NK cell 
counts after 6 months (Tables 6-8).
Discussion
Previous curcumin studies with early B-cell lymphoid 
malignancies have shown an improvement in disease mark-
ers in some patients.1-6 The addition of Ribraxx to curcumin 
therapy in patients who have reached a stable disease 
response does not appear to change this response but may 
have a positive clinical impact in the MGUS/SMM subset 
by increasing neutrophil counts and decreasing inflamma-
tion as determined by an improvement in the ESR.
Neutropenia is a common and serious complication in 
multiple myeloma and patients with early-stage disease. A 
neutropenic patient is at significant risk of bacterial or fun-
gal infections.22 The addition of Ribraxx to the curcumin 
administration appears to have been effective in increasing 
the neutrophil count in both the neutropenic MGUS/SMM 
patients and the patients with normal baseline neutrophil 
counts. This study is the first to show such positive effects 
of Ribraxx.
Whereas MGUS/SMM and stage 0/1 CLL both represent 
early B-cell lymphoid malignancies, patients present with 
different hematological and biochemical features. In multi-
ple myeloma of the IgG and IgA subtypes, significant cor-
relations have been found between ESR and the monoclonal 
proteins and between the ESR and percentageof plasma 
cells in bone marrow.23 Alexandrakis et al24 suggest that 
ESR is an independent prognostic factor for survival in 
patients with MM. Patients with earlier-stage disease may 
also show elevated levels of this acute phase protein, as evi-
dent by the raised ESR in our MGUS/SMM cohort. The 
Curcuforte/Ribraxx combination therapy showed a potent 
effect in reducing the raised ESR in 2 of 9 (22%) patients at 
month 2. This fall in ESR, despite no change in the parapro-
tein level, was an unexpected finding, perhaps resulting 
from a synergism in anti-inflammatory activity of both cur-
cumin and Ribraxx. One of these patients maintained the 
dramatic decrease in ESR.
Ribraxx has been previously shown to enhance NK cell–
mediated cytotoxicity but not increase NK cell number.10,11 
Table 7. Individual CD8 T-cell Countsa Over the 6-Month 
Study Period.
Patient 
Number Baseline
Month 
2
Month 
4
Month 
6
Percentage 
Change From 
Baseline
MGUS/SMM
 1 0.48 0.41 0.59 0.69 44
 2 0.37 0.5 0.23 0.28 –24
 3b 0.26 0.3 0.24 0.23 –12
 4 0.29 0.24 0.18 0.26 –10
 5 0.15 0.26 0.13 0.2 33
 7 0.04 0.06 0.05 0.12 200
 8 0.27 0.27 0.26 –4
 9b 0.34 0.34 0.35 0.35 3
10 0.27 0.44 0.51 0.51 89
Stage 0/1 CLL
 1 2.54 1.81 1.13 2.76 9
 2 0.37 1.33 0.52 0.52 41
 3 0.46 1.18 1.21 163
 4 1.18 0.57 0.96 1.06 –10
 5 1.64 1.83 1.49 1.71 4
 6 1.76 2.21 0.98 1.19 –32
 7b 1.33 1.9 1.98 1.03 –23
 8 1.6 1.6 2.17 2.18 36
 9 1.55 1.27 1.48 –5
Abbreviations: MGUS, monoclonal gammopathy of undetermined 
significance; SMM, smoldering multiple myeloma; CLL, chronic 
lymphocytic leukemia.
aNormal = 0.2×109/Lto 0.9×109/L.
bRibraxx only.
Table 8. Individual NK Cell Countsa Over the 6-Month Study 
Period.
Patient 
Number Baseline Month 2 Month 4 Month 6
Percentage 
Change From 
Baseline
MGUS/SMM
1 0.38 0.34 0.36 0.48 26
2 0.5 0.47 0.17 0.23 –54
3b 0.06 0.06 0.06 0.04 –33
4 0.34 0.5 0.42 0.58 71
5 0.44 0.34 0.25 0.41 –7
7 0.18 0.25 0.14 0.18 0
8 0.48 0.44 0.41 –15
9b 0.25 0.25 0.2 0.2 –20
10 0.14 0.24 0.22 0.18 29
Stage 0/1 CLL
1 2.54 1.2 1.13 2.07 –19
2 1.46 2.66 1.03 –30
3 0.31 0.94 0.91 194
4 1.01 0.72 0.96 1.06 5
5 0.55 0.61 0.5 0.57 4
6 1.17 1.1 0.39 0.51 –56
7b 1.33 0.95 0.99 1.03 –22
8 0.81 0.8 0.72 0.93 15
9 2.07 2.12 1.85 –11
Abbreviations: MGUS, monoclonal gammopathy of undetermined 
significance; SMM, smoldering multiple myeloma; CLL, chronic 
lymphocytic leukemia; NK, natural killer cells.
aNormal = 0.05×109/Lto 0.6×109/L.
bRibraxx only.
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Our study confirms these findings in the MGUS/SMM 
patients treated with the Curcuforte/Ribraxx combination 
therapy. However, cellactivation studies were not carried out.
Immunomodulation of CD4 T-cell, CD8 T-cell, and NK 
cell subsets has been previously shown following curcumin 
therapy.25-28 CD8 cytotoxic T lymphocytes are involved in 
antigen-specific tumor destruction, and CD4 T-cells are 
essential for helping the CD8 T-cell–dependent tumor erad-
ication.25 A study by Ghoneum and Agrawal29 demonstrated 
that Ribraxx enhances the generation of cytotoxic CD8 
T-cells. Because of the combination therapy of Curcuforte/
Ribraxx, the percentage of CD4 and CD8 T-cells increased 
in 3 of 9 (33%) patients in the MGUS/SMM group.
Our previous study with stage 0/1 CLL patients and 
Meriva curcumin6 found that 20% of patients demonstrated 
>20% decrease in ALC over 6 months. This decrease in 
ALC was accompanied by an increase in CD4, CD8, and 
NK cells. In the present study, Meriva curcumin was replaced 
by C3-complex Curcuforte, and Ribraxx was added to the 
regimen and showed a similar result, where 2 of 9 (22%) 
early CLL patients show a >20% decrease in ALC at 6 
months. A study by Ghoneum and Gollapudi14 showed that 
Ribraxx sensitizes the human leukemic HUT 78 cell line to 
death receptor (CD95)-induced apoptosis, perhaps provid-
ing a mechanism of clinical activity seen in these patients. 
As a result of the combination therapy with Curcuforte/
Ribraxx, the percentage of CD4 and CD8 T-cells increased 
in 2 of 9 (22%) patients in the stage 0/1 CLL group.
In conclusion, the addition of Ribraxx to curcumin ther-
apy may be valuable because of its ability to improve the 
clinical response in the MGUS/SMM patients through an 
increase in neutrophil count and a decrease in inflammation 
as determined by ESR and its immunomodulatory effect on 
CD4, CD8, and NK cells. Similarly stage 0/1 CLL patients 
may benefit through the combined immunomodulatory activ-
ity of both curcumin and Ribraxx and the proapoptotic effect 
of Ribraxx.
Our pilot study has the limitation of only a small number 
of patients in both groups. A larger randomized, placebo-
controlled study is recommended to further explore the 
value of Curcuforte/Ribraxx combination therapy in 
patients with early B-cell lymphoid malignancies
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